EnglishBACKGROUND: Tumor-infiltrating lymphocytes (TILs) evaluated in primary breast cancer (BC) convey prognostic information. Limited data in the metastatic setting are available. METHODS: Secondary lesions from 94 BC patients, 43 triple-negative (TN) and 51 HER2-positive, were evaluated for TILs and expression of CD8, FOXP3, and PD-L1 by immunohistochemistry. RESULTS: TILs levels on metastasis were generally low (median 5%) and did not differ between TN and HER2+ tumors. Younger patients showed significantly lower TILs (p = 0.002). In HER2+ patients, TILs were higher in lung metastases as compared to other sites (p = 0.038). TILs composition was different across metastatic sites: skin metastases presented higher FOXP3 (p = 0.002) and lower CD8/FOXP3 ratio (p = 0.032). Patients treated for metastatic BC prior to biopsy had lower CD8 (overall: p = 0.005, HER2+: p = 0.011, TN: p = 0.075). In TN patients, median overall survival (OS) was 11.8 and 62.9 months for patients with low and high TILs, respectively (HR 0.29, 95%CI 0.11-0.76, log-rank p = 0.008). CD8/FOXP3 ratio was also prognostic in TN patients (median OS 8.0, 13.2, and 54.0 months in 1st, 2nd and 3th tertile, log-rank p = 0.019). Both TILs and CD8/FOXP3 ratio were independent factors at multivariate analysis. Counterintuitively, in HER2+ BC, low TILs tumors showed better prognosis (median OS 53.7 vs 39.9 months in TILs low and TILs high, not statistically significant). CONCLUSIONS: Our findings indicate the relevance of TILs as prognostic biomarker for TNBC even in the advanced setting and provide novel hypothesis-generating data on potential sources of immune heterogeneity of metastatic BC.
Immune characterization of breast cancer metastases: prognostic implications / Dieci, Mv; Tsvetkova, V; Orvieto, E; Piacentini, F; Ficarra, G; Griguolo, G; Miglietta, F; Giarratano, T; Omarini, C; Bonaguro, S; Cappellesso, R; Aliberti, C; Vernaci, G; Giorgi, Ca; Faggioni, G; Tasca, G; Conte, P; Guarneri, V.. - In: BREAST CANCER RESEARCH. - ISSN 1465-542X. - 20:62(2018), pp. 1-1. [10.1186/s13058-018-1003-1]
| Data di pubblicazione: | 2018 | |
| Data di prima pubblicazione: | 22-giu-2018 | |
| Titolo: | Immune characterization of breast cancer metastases: prognostic implications. | |
| Autore/i: | Dieci, Mv; Tsvetkova, V; Orvieto, E; Piacentini, F; Ficarra, G; Griguolo, G; Miglietta, F; Giarratano, T; Omarini, C; Bonaguro, S; Cappellesso, R; Aliberti, C; Vernaci, G; Giorgi, Ca; Faggioni, G; Tasca, G; Conte, P; Guarneri, V. | |
| Autore/i UNIMORE: | ||
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1186/s13058-018-1003-1 | |
| Rivista: | ||
| Volume: | 20 | |
| Fascicolo: | 62 | |
| Pagina iniziale: | 1 | |
| Pagina finale: | 1 | |
| Codice identificativo ISI: | WOS:000436105900001 | |
| Codice identificativo Scopus: | 2-s2.0-85048933999 | |
| Codice identificativo Pubmed: | 29929548 | |
| Citazione: | Immune characterization of breast cancer metastases: prognostic implications / Dieci, Mv; Tsvetkova, V; Orvieto, E; Piacentini, F; Ficarra, G; Griguolo, G; Miglietta, F; Giarratano, T; Omarini, C; Bonaguro, S; Cappellesso, R; Aliberti, C; Vernaci, G; Giorgi, Ca; Faggioni, G; Tasca, G; Conte, P; Guarneri, V.. - In: BREAST CANCER RESEARCH. - ISSN 1465-542X. - 20:62(2018), pp. 1-1. [10.1186/s13058-018-1003-1] | |
| Tipologia | Articolo su rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | |
|---|---|---|---|
| Immune characterization of breast cancer metastases.pdf | Articolo principale | Versione dell'editore (versione pubblicata) | Open Access Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
Copyright © 2022